<DOC>
	<DOCNO>NCT01551745</DOCNO>
	<brief_summary>This Phase II study Vigil™ autologous tumor cell vaccine integrate bevacizumab . All patient Vigil™ prepare stored initial primary surgical debulking . Patients meet eligibility criterion receive Vigil™ 1.0 x 10e7 cells/intradermal injection every 4 week bevacizumab 10 mg/kg intravenously every 2 week .</brief_summary>
	<brief_title>Salvage Ovarian FANG™ Vaccine + Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>1 . Histologically confirm papillary serous endometrioid ovarian cancer . 2 . Previous randomization Gradalis , Inc. protocol CLPTL 105 ; observation arm ( Group B ) patient vaccine prepared CLPTL 105 otherwise qualify . 3 . Recurrent cisplatinum resistant/refractory disease ( defined appearance measurable evaluable lesion asymptomatic CA125 level great 100 u/mL two consecutive measurement intervene therapy . 4 . Successful manufacture 4 vial Vigil™ vaccine . 5 . Recovered clinically relevant toxicity relate prior therapy . 6 . ECOG PS 02 prior Vigil™ vaccine administration . 7 . Normal organ marrow function define : 1 . Absolute granulocyte count ≥1,500/mm3 2 . Absolute lymphocyte count ≥ 200/mm3 3 . Platelets ≥100,000/mm3 4 . Total bilirubin ≤1.5 x ULN 5 . AST ( SGOT ) /ALT ( SGPT ) /alkaline phosphatase ≤2.5 x ULN 6 . Creatinine &lt; 1.5 mg/dL 7 . INR &lt; 1.5 8 . Baseline blood pressure must 140/90 9 . Urine proteintocreatinine ratio &lt; 1.0 mg/dL . 10 . Patients must `` statin '' drug ≥ 2 week prior initiation therapy . 11 . Ability understand willingness sign write inform protocol specific consent . 1 . Surgery involve general anesthesia , chemotherapy , radiotherapy , steroid therapy , immunotherapy within 4 week prior vaccination . Chemotherapy within 3 week prior vaccination . Steroid therapy within 1 week prior vaccination . 2 . Major surgery within 6 week minor surgery within 2 week receive bevacizumab . 3 . Patient must receive investigational agent within 4 week prior study entry . 4 . Patients require parenteral hydration nutrition evidence partial bowel obstruction perforation . 5 . Patients history brain metastasis . 6 . Patients compromise pulmonary disease . 7 . Short term ( &lt; 30 day ) concurrent systemic steroid ≤ 0.25 mg/kg prednisone per day ( maximum 7.5 mg/day ) bronchodilator ( inhaled steroid ) permit ; steroid regimen and/or immunosuppressive exclude . 8 . Prior splenectomy . 9 . Prior malignancy ( exclude nonmelanoma carcinomas skin carcinoma situ cervix ) unless remission ≥ 2 year . 10 . Kaposi 's Sarcoma . 11 . Patients active bleed pathologic condition carry high risk bleed know bleed disorder , coagulopathy , tumor involve major blood vessel . 12 . History Stroke/Transient Ischemic Attack 13 . Use bleed diathesis 14 . Use anticoagulant 15 . Patients clinically significant cardiovascular disease include follow : 1 . Significant cardiac conduction abnormality ( e.g. , PR interval &gt; 0.24 sec second third degree AV block . 2 . Uncontrolled hypertension , define systolic blood pressure ( BP ) &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg . 3 . Myocardial infarction , cardiac arrhythmia , unstable angina within past 6 month . 4 . New York Heart Association grade II great congestive heart failure . 5 . Serious cardiac arrhythmia require medication . 6 . Grade II great peripheral vascular disease except episode ischemia &lt; 24 hour induration manage nonsurgically without permanent deficit 7 . History cerebrovascular accident within past 6 month . 8 . No significant traumatic injury within past 28 day . 16 . Uncontrolled infection psychiatric illness/social situation would limit compliance study requirement . 17 . Patients know HIV . 18 . Patients chronic Hepatitis B C infection . 19 . Patients uncontrolled autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Papillary Serous Ovarian Cancer</keyword>
	<keyword>Endometrioid Ovarian Cancer</keyword>
	<keyword>Epithelial Ovarian Cancer</keyword>
</DOC>